Pallas Capital Advisors LLC Lexicon Pharmaceuticals, Inc. Transaction History
Pallas Capital Advisors LLC
- $2.24 Billion
- Q1 2025
A detailed history of Pallas Capital Advisors LLC transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Pallas Capital Advisors LLC holds 36,208 shares of LXRX stock, worth $26,793. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,208Holding current value
$26,793% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LXRX
# of Institutions
135Shares Held
196MCall Options Held
310KPut Options Held
77.3K-
Artal Group S.A. Luxembourg, N4136MShares$101 Million100.0% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$7.32 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.56MShares$7.07 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY8.21MShares$6.08 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA3.69MShares$2.73 Million0.0% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $140M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...